Genmab AS

Genmab AS EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Genmab AS (GMAB) as of Nov 22, 2026 is -27.66 %. In the previous year, EBIT CAGR (5 Year) was -27.66 % — a change of 0.00% (lower).

EBIT CAGR 5Y

-27.66 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Genmab AS is 2025 -27.66 % . EBIT CAGR (5 Year) of Genmab AS was 2024 -27.66 % . It decreases by 0.00% lower compared to the previous year.

The Genmab AS EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2018
-27.66 USD
Jan 1, 2019
-27.66 USD
Jan 1, 2020
-27.66 USD
Jan 1, 2021
-27.66 USD
Jan 1, 2022
-27.66 USD
Jan 1, 2023
-27.66 USD
Jan 1, 2024
-27.66 USD
Jan 1, 2025
-27.66 USD
The Genmab AS EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
-27.66 %0.00%
-27.66 %0.00%
-27.66 %0.00%
-27.66 %0.00%
-27.66 %0.00%
-27.66 %0.00%
-27.66 %0.00%
-27.66 %0.00%
-27.66 %0.00%
-27.66 %0.00%
-27.66 %0.00%
-27.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

EBIT CAGR (5 Year) of Genmab AS is -27.66 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Genmab AS since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Genmab AS

All Key Metrics — Genmab AS